Alan Frazier


Mr. Frazier, founder and Chairman of Frazier Healthcare Partners, has a long track record of successful investments in both Life Sciences and Growth Buyout companies.

Mr. Frazier founded Frazier Healthcare Partners in 1991 and has led the firm in raising eleven institutional funds and managing nearly $4.2 billion in assets. During his 27 years as Managing Partner and Chairman, he has worked with entrepreneurs to build many leading healthcare companies, including Array (NASDAQ: ARRY), Tularik (acquired by Amgen), Rigel (NASDAQ: RIGL), CV Therapeutics (acquired by Gilead), VIVUS (NASDAQ: VVUS), Corixa (acquired by GSK), Cadence (acquired by Mallinckrodt), TridentUSA (acquired by Formation Capital), Packaging Coordinators, Inc. (acquired by Partners Group) and most recently, Abode Healthcare (acquired by Tailwind). He currently sits on the board of Orthotic Holdings.

Prior to founding Frazier, he was integrally involved in growing several successful healthcare companies into national prominence. Mr. Frazier served as Executive Vice President and Chief Financial Officer of Immunex Corporation, an early biotechnology company that discovered and developed the blockbuster drug Enbrel to treat rheumatoid arthritis and other autoimmune disorders. Later, he served as the Senior Financial Advisor and Chief Financial Officer of Affymax and worked on the spin-out of Affymetrix. Prior to Immunex, he was head of the Emerging Business Practice and co-head of the Technology Practice for the Seattle office of Arthur Young & Company (now, Ernst & Young).

Mr. Frazier currently serves on the UW Medicine Board and UW Medicine Strategic Initiatives Committee, both affiliated with the University of Washington School of Medicine.


University of Washington (B.A.)

Year Joined